GlassScriptPhysician profile
Lee T Austin
NPI 1306927074
$3,323.93
in general payments reported to CMS, 2019-2025
20 companies · $759 in 2025
The $759 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $189 · 2021: $621 · 2022: $356 · 2023: $49.11 · 2024: $1,090 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $1,024.55 | 2024 | |
| Abbvie INC. | $632.69 | 2019-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $414.01 | 2020-2025 | Entyvio, Gattex |
| Genzyme Corporation | $357.27 | 2022-2025 | |
| Janssen Biotech, INC. | $242.07 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.58 | 2019-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $94.79 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $85.23 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $76.91 | 2019-2021 | |
| Daiichi Sankyo INC. | $39.49 | 2019-2020 | |
| Digestive Care, INC. | $37.71 | 2019 | |
| Qol Medical, LLC | $32.46 | 2021 | |
| Phathom Pharmaceuticals, INC. | $30.77 | 2025 | Voquezna |
| Lilly USA, LLC | $30.46 | 2025 | Omvoh |
| Amgen INC. | $28.90 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.41 | 2021 | |
| Mirum Pharmaceuticals, INC. | $19.54 | 2025 | Livmarli |
| Ironwood Pharmaceuticals, INC | $19.51 | 2020 | |
| Celltrion USA INC. | $15.61 | 2025 | Vegzelma |
| Pfizer INC. | $13.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.